Track the GRIFOLS, S.A. share price and the full management transaction log of the company, a publicly traded company based in Spain. Shares are listed on the ES market, under the authority of CNMV. Operating in the Health Care sector, GRIFOLS, S.A. has recorded 30 public disclosures. Market capitalisation: €6.7bn. The latest transaction was filed on 3 July 2026 (Other). Among the most active insiders: Raimon Grifols Roura. Every trade is openly available.
30
Insider Decl.
n/a
Thresholds
€11m
15 ops.
Buy Volume
€2m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate GRIFOLS, S.A. Buy (bullish), based on 12 analysts. Average price target: €14.51.
41Σ signal
Buys €11m€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,928 of 28,928 companies
56.4
score / 100
Value
70
Quality
43
FCF yld9.1%
Earn yld5.9%
EV/EBITDA10.0x
ROE6.9%
Gross mgn38%
Net mgn5.3%
Debt/EBITDA5.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
35,000 shares@ €16.22100.0% of flowShareXXXXISINISIN ES0171996087CNMV:2021151851
25 of 30 declarations
About GRIFOLS, S.A.
GRIFOLS, S.A. is a Spanish company that specializes in the production of plasma-derived products and medications for the treatment of rare diseases. It is listed on the Spanish stock market, XMAD.